Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy

SIMPLE SUMMARY: While checkpoint blockade immunotherapy results in durable, complete responses in some patients, most cancer types are non-responsive and the majority of patients with cancers known to be responsive do not benefit from these therapies. Herein, we show that antigen directed T-cell pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantilla-Rojas, Carolina, Velasquez, Fred C., Morton, Janelle E., Clemente, Leticia C., Parra, Edwin R., Torres-Cabala, Carlos, Sevick-Muraca, Eva M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997812/
https://www.ncbi.nlm.nih.gov/pubmed/35406595
http://dx.doi.org/10.3390/cancers14071823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997812/
https://www.ncbi.nlm.nih.gov/pubmed/35406595
http://dx.doi.org/10.3390/cancers14071823

Ejemplares similares